Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06130384 · ClinicalTrials.gov registry record · Phase 4
Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.
A Phase 4 study, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 4
- Development phase
- 97
- Enrollment target
NCT06130384 is a Phase 4 study that has completed, run by Wills Eye. The registered enrollment target is 97 participants.
The verdict
NCT06130384, a Phase 4 study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 97 participants
- Enrollment target
Study Summary
The purpose of this prospective interventional study is to compare post-intravitreal injection pain between eyes receiving topical bromfenac versus artificial tears as an analgesic after intravitreal injection.
Interventions
- DRUG Use of bromfenac 0.09% to reduce intravitreal injection pain
- DRUG Use of artificial tears to reduce intravitreal injection pain
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2023-11-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06130384
The ClinicalTrials.gov registry entry for NCT06130384 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Use of bromfenac 0.09% to reduce intravitreal injection pain is the first listed.
NCT06130384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06130384 about?
NCT06130384 is a clinical study titled "Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.". The purpose of this prospective interventional study is to compare post-intravitreal injection pain between eyes receiving topical bromfenac versus artificial tears as an analgesic after intravitreal injection.
What is the current status of trial NCT06130384?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 97 participants. The study started on 2021-03-01. Estimated completion is 2023-11-15.
What interventions are being tested in trial NCT06130384?
The interventions under investigation include: Use of bromfenac 0.09% to reduce intravitreal injection pain (DRUG), Use of artificial tears to reduce intravitreal injection pain (DRUG).
Who is sponsoring clinical trial NCT06130384?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.